达沙替尼联合强化化疗治疗儿童、青少年及年轻成人费城染色体阳性急性淋巴细胞白血病:儿童肿瘤协作组AALL0622试验结果
儿童肿瘤协作组AALL0622试验在60例新诊断费城染色体阳性急性淋巴细胞白血病患者(1-30岁)中评估达沙替尼联合强化化疗的安全性和可行性,5年总生存率和无事件生存率分别为86%±5%和60%±7%,与使用伊马替尼的AALL0031试验结果相似,IKZF1缺失与更差的生存相关。
要点
- 达沙替尼联合强化化疗耐受良好,5年OS为86%±5%,EFS为60%±7%。
- 标准风险组(n=48)5年OS为87%±5%,EFS为61%±7%,19%接受HSCT。
- IKZF1缺失见于56%的受检患者,与总体和标准风险组显著更差的OS和EFS相关。
核心结论
- 达沙替尼联合化疗耐受良好, outcomes与COG AALL0031中伊马替尼联合相同化疗的结果相似。
- 结果支持将HSCT限制用于慢反应者,并提示移植可能在快速反应且伴IKZF1缺失的患者中具有潜在作用。
研究设计与样本
- 儿童肿瘤协作组(COG)AALL0622试验(Bristol Myers Squibb trial CA180-204)为单臂研究,测试在诱导第15天开始将达沙替尼加入强化化疗的安全性和可行性。
- 纳入60例新诊断费城染色体阳性急性淋巴细胞白血病患者,年龄1至30岁。
- 基于慢反应的高危患者和无论反应如何有匹配家庭供者的患者 recommended 接受异基因造血干细胞移植(HSCT),至少治疗11周后;基于快速反应的标准风险患者接受化疗加达沙替尼额外120周。
- 有明显中枢神经系统白血病患者接受颅脑照射。
主要发现
- 60例 eligible 患者入组,5年总生存(OS)率和无事件生存(EFS)率(±标准差[SD])总体为86%±5%和60%±7%。
- 标准风险患者(n=48;19%接受HSCT)5年OS和EFS分别为87%±5%和61%±7%;高危患者(n=9;89%接受HSCT)分别为89%±13%和67%±19%。
- 5年中枢神经系统复发累积发生率(±SD)为15%±6%。
- 与COG AALL0031(相同化疗联合持续伊马替尼)相比,5年OS为81%±6% vs 86%±5%(P=.63),5年无病生存率为68%±7% vs 60%±7%(P=0.31),分别为AALL0031 vs AALL0622。
- IKZF1缺失见于56%的受检患者,与总体和标准风险患者显著更差的OS和EFS相关。
关键数值与推荐
- 达沙替尼从诱导第15天开始加入强化化疗。
- 基于慢反应的高危患者和无论反应如何有匹配家庭供者的患者 recommended 接受异基因HSCT,至少治疗11周后。
- 基于快速反应的标准风险患者接受化疗加达沙替尼额外120周。
- 有明显中枢神经系统白血病患者接受颅脑照射。
临床怎么用
- 达沙替尼联合强化化疗耐受良好, outcomes与伊马替尼联合相同化疗相似。
- 作者认为结果支持将HSCT限制用于慢反应者,并建议移植可能在快速反应且伴IKZF1缺失的患者中具有潜在作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Addition of imatinib to intensive chemotherapy improved survival for children and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Compared with imatinib, dasatinib has increased potency, CNS penetration, and activity against imatinib-resistant clones. Patients and Methods Children's Oncology Group (COG) trial AALL0622 (Bristol Myers Squibb trial CA180-204) tested safety and feasibility of adding dasatinib to intensive chemotherapy starting at induction day 15 in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia age 1 to 30 years. Allogeneic hematopoietic stem-cell transplantation (HSCT) was recommended for patients at high risk based on slow response and for those with a matched family donor regardless of response after at least 11 weeks of therapy. Patients at standard risk based on rapid response received chemotherapy plus dasatinib for an additional 120 weeks. Patients with overt CNS leukemia received cranial irradiation. Results Sixty eligible patients were enrolled. Five-year overall (OS) and event-free survival rates (± standard deviations [SD]) were 86% ± 5% and 60% ± 7% overall, 87% ± 5% and 61% ± 7% for standard-risk patients (n = 48; 19% underwent HSCT), and 89% ± 13% and 67% ± 19% for high-risk patients (n = 9; 89% underwent HSCT), respectively. Five-year cumulative incidence (± SD) of CNS relapse was 15% ± 6%. Outcomes (± SDs) were similar to those in COG AALL0031, which used the same chemotherapy with continuous imatinib: 5-year OS of 81% ± 6% versus 86% ± 5% ( P = .63) and 5-year disease-free survival of 68% ± 7% versus 60% ± 7% ( P = 0.31) for AALL0031 versus AALL0622, respectively. IKZF1 deletions, present in 56% of tested patients, were associated with significantly inferior OS and event-free survival overall and in standard-risk patients. Conclusion Dasatinib was well tolerated with chemotherapy and provided outcomes similar to those with imatinib in COG AALL0031, where all patients received cranial irradiation. Our results support limiting HSCT to slow responders and suggest a potential role for transplantation in rapid responders with IKZF1 deletions.
引用
- Slayton WB, Schultz KR, Kairalla JA, et al. Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. J Clin Oncol. 2018. PMID: 29812996. doi:10.1200/JCO.2017.76.7228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。